Management of Latent Tuberculosis Infection in Solid Organ Transplant Candidates: Short Regimens
Main Article Content
Jacques Simkins, MD
http://orcid.org/0000-0001-9626-0760
Yoichiro Natori
Shweta Anjan
Giselle Guerra
Rodrigo Vianna
http://orcid.org/0000-0001-9626-0760
Yoichiro Natori
Shweta Anjan
Giselle Guerra
Rodrigo Vianna
Abstract
Tuberculosis reactivation causes significant morbidity and mortality especially in immunocompromised patients such as solid organ transplant (SOT) recipients. Therefore, treating latent tuberculosis infection (LTBI) is critical. The treatment of LTBI with former first line regimen, isoniazid monotherapy for 9 months, can be challenging, as it is associated with higher toxicity risk and lower treatment completion rates. Isoniazid monotherapy for 9 months is more likely to cause liver toxicity compared to other regimens and its rate of completion can be lower than 50%. As of result of this, there has been a shift in the treatment of LTBI. The following short-regimens: 3 months of weekly isoniazid plus rifapentine, 4 months of daily rifampin and 3 months of daily isoniazid plus rifampin, have replaced 9-month isoniazid monotherapy as first line treatments for LTBI, after the new guidelines of LTBI management were published in 2020 by the Centers for Disease Control and Prevention (CDC) and National Tuberculosis Controllers Association. These short regimens for LTBI are effective and safe in SOT candidates. However, close monitoring for drug-drug interactions are paramount.
Article Details
How to Cite
SIMKINS, Jacques et al.
Management of Latent Tuberculosis Infection in Solid Organ Transplant Candidates: Short Regimens.
Medical Research Archives, [S.l.], v. 10, n. 10, oct. 2022.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/3194>. Date accessed: 21 nov. 2024.
doi: https://doi.org/10.18103/mra.v10i10.3194.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Subramanian AK, Theodoropoulos NM; Infectious Diseases Community of Practice of the American Society of Transplantation. Mycobacterium tuberculosis infections in solid organ transplantation: Guidelines from the infectious diseases community of practice of the American Society of Transplantation. Clin Transplant. 2019;33(9):e13513. doi: 10.1111/ctr.13513.
2. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
3. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847-50.
4. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.
5. Centers for Disease Control and Prevention (CDC), Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(15):289-91.
6. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1-12. doi: 10.1185/03007995.2012.747952.
7. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.
8. Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin TR, Castro KG, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012. PLoS One. 2015;10:e0140881.
9. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655. doi: 10.1183/13993003.00655-2019.
10. Collins JM, Stout JE, Ayers T, Hill AN, Katz DJ, Ho CS, et al. Tuberculosis Epidemiologic Studies Consortium. Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth-United States, 2012-2017. Clin Infect Dis. 2021;73(9):e3468-e3475. doi: 10.1093/cid/ciaa1662.
11. Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, el al. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. PLoS One. 2021;16(4):e0249012. doi: 10.1371/journal.pone.0249012. eCollection 2021.
12. Simkins J, Kraus K, Morris MI. Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates. Transpl Infect Dis. 2016;18(1):5-13. doi: 10.1111/tid.12476.
13. Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Schäfers HJ, el al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009;34(3):702-10. doi: 10.1183/09031936.00013409.
14. Wigg AJ, Narayana SK, Anwar S, Ramachandran J, Muller K, Chen JW, et al. High rates of indeterminate interferon-gamma release assays for the diagnosis of latent tuberculosis infection in liver transplantation candidates Transpl Infect Dis. 2019;21(3):e13087. doi: 10.1111/tid.13087.
15. Hand J, Sigel K, Huprikar S, Hamula C, Rana M. Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON ® -TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant. Transpl Infect Dis. 2018;20:e12845. doi: 10.1111/tid.12845.
16. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17:265. doi: 10.1186/s12879-017-2377-x.
17. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
18. Stout JE, Sterling TR, Horsburgh CR Jr. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;381(11):e23. doi: 10.1056/NEJMc1908492.
19. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557-566. doi: 10.1002/pds.4423.
20. Wang TY, Feng JY, Shu CC, Lee SS, Chen CY, Wei YF, et al. Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Front Microbiol. 2022;13:821066. doi: 10.3389/fmicb.2022.821066.
21. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, et al. TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167:689–97.
22. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67:723–6.
23. Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. Transplantation. 2017;101(6):1468-1472.
24. de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation. 2014;97(2):206-11.
25. Simkins J, Donato-Santana C, Morris MI, Abbo LM, Camargo JF, Anjan S, et al. Treatment of latent tuberculosis infection with short-course regimens in potential living kidney donors. Transpl Infect Dis. 2020;22(2):e13244. doi: 10.1111/tid.13244.
26. Simkins J, Morris MI, Abbo LM, Camargo JF. Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates. Transpl Int. 2017;30(1):108-109.
27. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440–53.
28. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454–63.
29. Ronald LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, Benedetti A, Boivin JF, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. Eur Respir J. 2020;55(3):1902048. doi: 10.1183/13993003.02048-2019.
30. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation. 2007;83(12):1557-62.
31. Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007;25:300–4.
32. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670–6
33. Guirao-Arrabal E, Santos F, Redel J, Vaquero JM, Torre-Cisneros J. Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. Clin Transplant. 2017;31(3). doi: 10.1111/ctr.12901.
2. Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, et al. Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep. 2020;69(1):1-11. doi: 10.15585/mmwr.rr6901a1.
3. Comstock GW. How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int J Tuberc Lung Dis. 1999;3(10):847-50.
4. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. TB Trials Consortium PREVENT TB Study Team. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155–66.
5. Centers for Disease Control and Prevention (CDC), Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000. MMWR Morb Mortal Wkly Rep. 2001;50(15):289-91.
6. Baciewicz AM, Chrisman CR, Finch CK, Self TH. Update on rifampin, rifabutin, and rifapentine drug interactions. Curr Med Res Opin. 2013;29(1):1-12. doi: 10.1185/03007995.2012.747952.
7. Houben RM, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016;13:e1002152.
8. Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin TR, Castro KG, et al. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012. PLoS One. 2015;10:e0140881.
9. Cohen A, Mathiasen VD, Schön T, Wejse C. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3):1900655. doi: 10.1183/13993003.00655-2019.
10. Collins JM, Stout JE, Ayers T, Hill AN, Katz DJ, Ho CS, et al. Tuberculosis Epidemiologic Studies Consortium. Prevalence of Latent Tuberculosis Infection Among Non-US-Born Persons by Country of Birth-United States, 2012-2017. Clin Infect Dis. 2021;73(9):e3468-e3475. doi: 10.1093/cid/ciaa1662.
11. Mirzazadeh A, Kahn JG, Haddad MB, Hill AN, Marks SM, Readhead A, el al. State-level prevalence estimates of latent tuberculosis infection in the United States by medical risk factors, demographic characteristics and nativity. PLoS One. 2021;16(4):e0249012. doi: 10.1371/journal.pone.0249012. eCollection 2021.
12. Simkins J, Kraus K, Morris MI. Demographics and prevalence of positive QuantiFERON-TB Gold In-Tube test in renal transplant candidates. Transpl Infect Dis. 2016;18(1):5-13. doi: 10.1111/tid.12476.
13. Sester U, Wilkens H, van Bentum K, Singh M, Sybrecht GW, Schäfers HJ, el al. Impaired detection of Mycobacterium tuberculosis immunity in patients using high levels of immunosuppressive drugs. Eur Respir J. 2009;34(3):702-10. doi: 10.1183/09031936.00013409.
14. Wigg AJ, Narayana SK, Anwar S, Ramachandran J, Muller K, Chen JW, et al. High rates of indeterminate interferon-gamma release assays for the diagnosis of latent tuberculosis infection in liver transplantation candidates Transpl Infect Dis. 2019;21(3):e13087. doi: 10.1111/tid.13087.
15. Hand J, Sigel K, Huprikar S, Hamula C, Rana M. Tuberculosis after liver transplantation in a large center in New York City: QuantiFERON ® -TB Gold-based pre-transplant screening performance and active tuberculosis post-transplant. Transpl Infect Dis. 2018;20:e12845. doi: 10.1111/tid.12845.
16. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Quach P, et al. Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses. BMC Infect Dis. 2017;17:265. doi: 10.1186/s12879-017-2377-x.
17. Swindells S, Ramchandani R, Gupta A, Benson CA, Leon-Cruz J, Mwelase N, et al. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;380(11):1001-1011. doi: 10.1056/NEJMoa1806808.
18. Stout JE, Sterling TR, Horsburgh CR Jr. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019;381(11):e23. doi: 10.1056/NEJMc1908492.
19. Pease C, Hutton B, Yazdi F, Wolfe D, Hamel C, Barbeau P, et al. A systematic review of adverse events of rifapentine and isoniazid compared to other treatments for latent tuberculosis infection. Pharmacoepidemiol Drug Saf. 2018;27(6):557-566. doi: 10.1002/pds.4423.
20. Wang TY, Feng JY, Shu CC, Lee SS, Chen CY, Wei YF, et al. Plasma Concentrations of sTREM-1 as Markers for Systemic Adverse Reactions in Subjects Treated With Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection. Front Microbiol. 2022;13:821066. doi: 10.3389/fmicb.2022.821066.
21. Belknap R, Holland D, Feng PJ, Millet JP, Caylà JA, Martinson NA, et al. TB Trials Consortium iAdhere Study Team. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection: a randomized trial. Ann Intern Med. 2017;167:689–97.
22. Borisov AS, Bamrah Morris S, Njie GJ, Winston CA, Burton D, Goldberg S, et al. Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2018;67:723–6.
23. Simkins J, Abbo LM, Camargo JF, Rosa R, Morris MI. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates. Transplantation. 2017;101(6):1468-1472.
24. de Castilla DL, Rakita RM, Spitters CE, Narita M, Jain R, Limaye AP. Short-course isoniazid plus rifapentine directly observed therapy for latent tuberculosis in solid-organ transplant candidates. Transplantation. 2014;97(2):206-11.
25. Simkins J, Donato-Santana C, Morris MI, Abbo LM, Camargo JF, Anjan S, et al. Treatment of latent tuberculosis infection with short-course regimens in potential living kidney donors. Transpl Infect Dis. 2020;22(2):e13244. doi: 10.1111/tid.13244.
26. Simkins J, Morris MI, Abbo LM, Camargo JF. Severe hypertension after initiation of rifapentine/isoniazid for latent tuberculosis in renal transplant candidates. Transpl Int. 2017;30(1):108-109.
27. Menzies D, Adjobimey M, Ruslami R, Trajman A, Sow O, Kim H, et al. Four months of rifampin or nine months of isoniazid for latent tuberculosis in adults. N Engl J Med. 2018;379:440–53.
28. Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Obeng Baah J, et al. Safety and side effects of rifampin versus isoniazid in children. N Engl J Med. 2018;379:454–63.
29. Ronald LA, FitzGerald JM, Bartlett-Esquilant G, Schwartzman K, Benedetti A, Boivin JF, et al. Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs. Eur Respir J. 2020;55(3):1902048. doi: 10.1183/13993003.02048-2019.
30. Jahng AW, Tran T, Bui L, Joyner JL. Safety of treatment of latent tuberculosis infection in compensated cirrhotic patients during transplant candidacy period. Transplantation. 2007;83(12):1557-62.
31. Geijo MP, Herranz CR, Vaño D, García AJ, García M, Dimas JF. [Short-course isoniazid and rifampin compared with isoniazid for latent tuberculosis infection: a randomized clinical trial]. Enferm Infecc Microbiol Clin. 2007;25:300–4.
32. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis. 2005;40:670–6
33. Guirao-Arrabal E, Santos F, Redel J, Vaquero JM, Torre-Cisneros J. Efficacy and safety of short-term treatment with isoniazid and rifampicin for latent tuberculosis infection in lung transplant candidates. Clin Transplant. 2017;31(3). doi: 10.1111/ctr.12901.